WILMINGTON, DE — Incyte (Nasdaq: INCY) will present new clinical data from its oncology pipeline at the upcoming European Society of Medical Oncology (ESMO) Congress, set for October 17–21 in Berlin. The presentations will include early-stage findings for two promising investigational therapies targeting advanced solid tumors, highlighting the company’s focus on precision medicine and immune-oncology.
Among the highlights are initial Phase 1 results for INCB161734, an oral inhibitor targeting G12D-mutated KRAS, and INCA33890, a bispecific antibody directed at PD-1 and TGFβR2. Both candidates are designed to treat patients with difficult-to-manage tumors.
“We’re looking forward to presenting the latest findings across our oncology portfolio at this year’s congress,” said Dr. Pablo J. Cagnoni, President and Head of Research and Development at Incyte. “These data underscore the importance of establishing treatment options for advanced solid tumors and speak to the potential of INCA33890 and INCB161734 as personalized therapies to enhance outcomes for patients with cancer across a range of tumor types.”
Key Presentations at ESMO 2025
- INCB161734 (KRAS G12D Inhibitor): A first-in-human, Phase 1 study evaluating the safety, pharmacokinetics, and preliminary efficacy of INCB161734 in patients with advanced or metastatic solid tumors will be presented during the Developmental Therapeutics Proffered Paper Session on October 19.
- INCA33890 (PD-1/TGFβR2 Bispecific Antibody): Early clinical data from a Phase 1 trial assessing this novel immunotherapy will be shared in the Investigational Immunotherapy Mini Oral Session on October 17.
- INCAGN2385 (LAG-3 Pathway): Incyte will also present results from a Phase 2 randomized trial evaluating the anti–PD-1 antibody retifanlimab alone and in combination with anti-LAG3 and anti-TIM3 agents in PD-L1 positive, recurrent or metastatic head and neck squamous cell carcinoma (HNSCC). This data will be featured in the Head and Neck Cancer Mini Oral Session on October 19.
Incyte’s participation in ESMO underscores its strategic commitment to expanding its oncology footprint through highly targeted, biology-driven drug development. The company continues to diversify its pipeline with novel immuno-oncology agents and next-generation inhibitors aimed at tumor-specific mutations.
All accepted abstracts will be made publicly available on October 13 through ESMO’s website and the Annals of Oncology Abstract Book supplement.
For the latest news on everything happening in Chester County and the surrounding area, be sure to follow MyChesCo on Google News and MSN.